Uptake of 3H-vincristine in Mouse Tumors During Radiotherapy
Author Information
Author(s): G.D. Zanelli, L. Rota, M. Trovo, E. Grigoletto, M. Roncadin
Primary Institution: Clinical Research Centre, Watford Road, Harrow, Middlesex, UK
Hypothesis
How does the timing of 3H-vincristine injection affect its uptake in mouse tumors during fractionated radiotherapy?
Conclusion
The uptake of 3H-vincristine in tumors varies significantly during fractionated radiotherapy, with peaks observed after certain fractions.
Supporting Evidence
- Maximum levels of 3H in the tumors are found when the tracer is injected 4 hours after irradiation.
- During the course of daily irradiation, the pattern of uptake varies considerably but reproducibly.
- There are peaks of uptake after 7, 13, and 22 fractions of 2.0 Gy.
Takeaway
This study looked at how a special drug gets into tumors while they are being treated with radiation, finding that the timing of the drug matters a lot.
Methodology
The study involved injecting 3H-vincristine into mice with tumors at various times after radiation treatment and measuring the drug's uptake.
Limitations
The study is limited to a specific mouse tumor model and may not directly apply to human tumors.
Participant Demographics
Eight- to twelve-week-old male CBA/He mice were used.
Want to read the original?
Access the complete publication on the publisher's website